相关实验视频

Updated: Jan 11, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.5K

化学放射治疗前和后的奥西默提尼布用于不可切除的III期EGFR突变NSCLC:NEOLA试验协议

Jacqueline V Aredo1, Nir Peled2, Edurne Arriola3

  • 1Department of Medicine, Division of Oncology, Stanford University School of Medicine and Stanford Cancer Institute, Stanford, CA, USA.

Future oncology (London, England)
|November 14, 2025
PubMed
概括

本研究是NCT06194448的临床试验注册,于2024年1月5日开始. 关于该研究的进一步细节.

关键词:
在 EGFR 基因突变.这是一种EGFR-tyrosine kinase抑制剂.化学疗法或放射治疗奥西米尔丁尼布 (osimertinib) 是一种第三阶段NSCLCLC的第三阶段不能切割的不可切割的

更多相关视频

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.6K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.4K

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K